ET-1 stimulation protects CLL cells from spontaneous apoptosis, stimulates proliferation and reduces leukemic cells sensitivity to the phosphoinositide-3-kinase δ inhibitor idelalisib and to fludarabine. Here, EDN1 is linked to B-cell chronic lymphocytic leukemia.